Product Images Everolimus

This is a description about Everolimus Tablets. Each tablet contains 0.25 mg of everolimus USP. The dosage information is available in the package insert. It is recommended to store the tablets at temperatures between 20°C to 25°C, protecting them from light and moisture. The packaging is child-resistant, and the medication should be kept out of reach of children. Patients experiencing side effects should contact their doctor, and can also report side effects to the FDA at 1-800-FDA-1088. The tablets are manufactured by Biocon Pharma Inc. in Iselin, NJ, USA and in Bengaluru, India.*

This is a description of Everolimus Tablets, which contain 0.5 mg of everolimus USP. Each package consists of 60 tablets and a medication guide for patients. The dosage information can be found in the package insert. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with permissible excursions between 15°C and 30°C (59° and 86°F). It is important to protect the tablets from light and moisture. The package is child-resistant to keep it out of children's reach. Patients should contact their doctor for advice on side effects and can report them to the FDA at 1-800-FDA-1088. The tablets are manufactured by Biocon Pharma, with the addresses listed for both the manufacturing and distribution locations.*

This is a description of Everolimus tablets containing 0.75 mg of everolimus USP. The dosage information is available in the package insert. The tablets should be stored between 15°C and 30°C (59°F and 86°F) with no excursions permitted. The medication guide enclosed in the package should be dispensed to each patient. The packaging is child-resistant and should be kept out of reach of children. In case of side effects, contact a doctor or report them to the FDA. The tablets are manufactured for Biocon Pharma Inc. in Iselin, NJ, USA, and manufactured by Biocon Pharma Ltd. in Bengaluru, India.*

This is a description of Everolimus tablets containing 1 mg of everolimus USP. The medication guide included should be dispensed to each patient. It is advised to store the tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). The package is child-resistant and should be kept away from light and moisture. Patients are encouraged to contact a doctor for medical advice regarding side effects and can report them to the FDA at 1-800-FDA-1088. The tablets are manufactured by Biocon Pharma Inc. in Iselin, NJ, USA, and in Bengaluru, India.*

This is a medical data point showing a GFR (MDRD 4) value of 110 mL/min/1.73m^2. The information also includes details about the visit window and treatment group, which involves S-5-5 EVR+Reduced TAC #-4-4 TAC Control.*

This is a description for Everolimus tablets, which come in a strength of 0.75 mg. The tablets are indicated for prescription use only and are manufactured by Biocon Pharma Limited in Bengaluru, India. The specific National Drug Code (NDC) for these tablets is 70377-071-21.*